<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Clinical Validation - Skolyn Documentation</title>
<link href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700&family=Google+Sans+Text:wght@400;500&display=swap" rel="stylesheet">
<style>*{margin:0;padding:0;box-sizing:border-box}body{font-family:'Google Sans Text','Google Sans',Roboto,'Helvetica Neue',Arial,sans-serif;max-width:900px;margin:0 auto;padding:48px 40px;color:#1d1d1f;line-height:1.8;font-size:15px}.doc-id-bar{display:flex;justify-content:space-between;align-items:center;padding:12px 20px;background:#f8f9fa;border:1px solid #e8eaed;border-radius:8px;margin-bottom:24px;font-size:13px;color:#5f6368}.doc-id-bar .doc-id{font-family:'Google Sans',sans-serif;font-weight:700;color:#1a73e8;font-size:14px;letter-spacing:.5px}.doc-id-bar .doc-class{padding:4px 12px;background:#e8f0fe;color:#1a73e8;border-radius:100px;font-weight:500;font-size:12px}.doc-header{border-bottom:3px solid #00897b;padding-bottom:28px;margin-bottom:40px}.doc-header h1{font-family:'Google Sans',sans-serif;font-size:32px;font-weight:700;margin-bottom:8px}.doc-header .subtitle{font-size:16px;color:#5f6368;margin-bottom:16px}.doc-header .meta-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px;font-size:13px;color:#5f6368}.doc-header .meta-item{display:flex;align-items:center;gap:6px}.doc-header .meta-item strong{color:#1d1d1f}h2{font-family:'Google Sans',sans-serif;font-size:22px;color:#00897b;margin:40px 0 16px;padding-bottom:8px;border-bottom:1px solid #e8eaed}h3{font-family:'Google Sans',sans-serif;font-size:17px;color:#202124;margin:28px 0 12px}p{margin-bottom:14px}ul,ol{margin:0 0 18px 24px}li{margin-bottom:8px}table{width:100%;border-collapse:collapse;margin:16px 0 24px;font-size:13px}th,td{padding:10px 14px;text-align:left;border:1px solid #dadce0}th{background:#e0f2f1;font-weight:600;color:#00695c}td{color:#3c4043}tr:nth-child(even) td{background:#fafafa}code{background:#f1f3f4;padding:2px 8px;border-radius:4px;font-size:13px}.signature-section{margin-top:64px;page-break-inside:avoid}.signature-section .section-title{font-family:'Google Sans',sans-serif;font-size:18px;font-weight:700;color:#1d1d1f;margin-bottom:24px;padding-bottom:12px;border-bottom:2px solid #1d1d1f}.signature-grid{display:grid;grid-template-columns:1fr 1fr;gap:48px}.signature-block{border:1px solid #dadce0;border-radius:12px;padding:32px;background:#fafafa}.signature-block .role{font-family:'Google Sans',sans-serif;font-size:16px;font-weight:700;margin-bottom:4px}.signature-block .name{font-size:14px;color:#5f6368;margin-bottom:24px}.signature-line{border-bottom:1px solid #1d1d1f;height:48px;margin-bottom:8px}.signature-label{font-size:12px;color:#80868b;margin-bottom:16px}.stamp-area{border:2px dashed #dadce0;border-radius:8px;height:100px;display:flex;align-items:center;justify-content:center;color:#80868b;font-size:12px;margin-top:16px}.doc-footer{margin-top:48px;padding-top:24px;border-top:2px solid #e8eaed;font-size:12px;color:#5f6368;text-align:center}.doc-footer p{margin-bottom:4px}@media print{body{max-width:100%;padding:20px;font-size:12px}.signature-section{page-break-before:always}}</style>
</head>
<body>

<div class="doc-id-bar"><span class="doc-id">SKL-AI-002</span><span>Skolyn Platform Documentation</span><span class="doc-class">CONFIDENTIAL</span></div>

<div class="doc-header">
  <h1>Clinical Validation</h1>
  <div class="subtitle">Multi-Site Clinical Trial Design, Validation Methodology, Performance Benchmarks, and Regulatory Evidence Generation</div>
  <div class="meta-grid">
    <div class="meta-item"><strong>Version:</strong> 3.0</div>
    <div class="meta-item"><strong>Last Updated:</strong> February 2026</div>
    <div class="meta-item"><strong>Classification:</strong> Confidential</div>
    <div class="meta-item"><strong>Owner:</strong> Clinical Affairs</div>
  </div>
</div>

<h2>1. Overview</h2>
<p>Clinical validation is the process of demonstrating that an AI medical device performs safely and effectively for its intended use in a clinically representative setting. For Skolyn's Terbium OS platform, clinical validation encompasses retrospective studies on curated datasets, prospective reader studies comparing AI-assisted vs. unassisted radiologist performance, and real-world evidence collection from production deployments. The validation program is designed to generate the clinical evidence required for FDA 510(k)/De Novo clearance, EU MDR CE marking (via Notified Body assessment), and MHRA UKCA registration. Each Terbium OS analysis module undergoes independent clinical validation with module-specific endpoints, reference standards, and sample size calculations based on the statistical power needed to demonstrate clinically meaningful performance.</p>

<h2>2. Validation Methodology</h2>
<h3>2.1 Study Design Framework</h3>
<p>Skolyn follows a three-phase validation framework: Phase 1 (Stand-alone Performance) evaluates AI performance on retrospective datasets with established ground truth, measuring sensitivity, specificity, AUC, and positive/negative predictive values. Phase 2 (Reader Study) evaluates radiologist performance with and without AI assistance in a multi-reader multi-case (MRMC) crossover design, measuring the difference in diagnostic accuracy (AUC), reading time, inter-reader agreement, and false positive/negative rates. Phase 3 (Prospective Deployment) monitors AI performance in live clinical workflows with real-world data, measuring accuracy against the clinical reference standard (follow-up imaging, pathology, clinical outcomes), alert appropriateness, and clinician satisfaction/trust scores.</p>

<h3>2.2 Reference Standards</h3>
<p>Ground truth definitions follow the STARD (Standards for Reporting Diagnostic Accuracy Studies) guidelines. For each clinical endpoint, the reference standard is the highest-fidelity ground truth available: histopathology for oncologic findings, surgical/procedural confirmation for anatomical findings, follow-up imaging for temporal progression, and expert panel consensus (minimum 3 subspecialty radiologists) for findings where invasive ground truth is not available. Ground truth labels are established by expert annotators blinded to the AI predictions, with inter-annotator agreement measured and reported.</p>

<h2>3. Sample Size and Statistical Design</h2>
<p>Sample size calculations use the method of Obuchowski (2005) for MRMC reader studies, targeting 80% power to detect a clinically meaningful difference in AUC of 0.03 at alpha=0.05. For typical CXR pathology detection with estimated reader variability, this requires approximately 300-500 cases (enriched for positive cases to 30-50% prevalence) and 10-15 readers per study arm. For standalone performance studies, sample size is calculated using the exact binomial method targeting the lower bound of the 95% CI for sensitivity above the predefined clinical threshold (e.g., sensitivity &gt;90%). All statistical analyses use bootstrapped 95% confidence intervals and non-parametric tests to avoid distributional assumptions.</p>

<h2>4. Multi-Site Clinical Evidence</h2>
<table>
  <tr><th>Module</th><th>Validation Type</th><th>Sites</th><th>Cases</th><th>Primary Endpoint</th></tr>
  <tr><td>CXR 14-Path</td><td>MRMC Reader Study</td><td>5</td><td>1,200</td><td>AUC per pathology</td></tr>
  <tr><td>Brain MRI</td><td>Retrospective + Prospective</td><td>3</td><td>800</td><td>Sensitivity for tumors</td></tr>
  <tr><td>Mammography</td><td>Retrospective Screening</td><td>4</td><td>80,000</td><td>Cancer detection rate</td></tr>
  <tr><td>Head CT</td><td>Emergency Reader Study</td><td>6</td><td>2,000</td><td>Hemorrhage sensitivity</td></tr>
  <tr><td>MSK X-Ray</td><td>ED Prospective</td><td>4</td><td>5,000</td><td>Fracture miss rate reduction</td></tr>
</table>

<h2>5. Continuous Performance Monitoring</h2>
<p>Post-market clinical follow-up (PMCF) is mandated by EU MDR and implemented through Skolyn's continuous monitoring infrastructure. Deployed models are continuously evaluated against radiologist final reports as a proxy ground truth, with statistical process control charts monitoring sensitivity, specificity, and confidence calibration over time. Alert thresholds trigger clinical safety review when performance metrics degrade by more than 2 standard deviations from the validation baseline. Quarterly PMCF reports are generated automatically and submitted to the quality management system for regulatory review.</p>

<h2>6. Evidence Documentation</h2>
<p>All validation evidence is documented according to the EQUATOR network reporting guidelines: STARD for diagnostic accuracy studies, CONSORT for randomized studies, and TRIPOD for prediction model validation. Clinical evaluation reports (CERs) following MDCG 2020-13 guidance synthesize clinical evidence with systematic literature review, presenting the benefit-risk analysis required by Notified Bodies. The evidence package includes study protocols, statistical analysis plans, raw datasets (de-identified), analysis scripts (for reproducibility), and final study reports with all pre-specified and post-hoc analyses.</p>

<h2>7. Document Revision History</h2>
<table>
  <tr><th>Version</th><th>Date</th><th>Author</th><th>Changes</th></tr>
  <tr><td>1.0</td><td>2024-06-15</td><td>Clinical Affairs</td><td>Initial release</td></tr>
  <tr><td>2.0</td><td>2025-06-01</td><td>Clinical Affairs</td><td>Added PMCF, MRMC design</td></tr>
  <tr><td>3.0</td><td>2026-02-10</td><td>Clinical Affairs</td><td>Updated multi-site evidence</td></tr>
</table>

<div class="signature-section">
  <div class="section-title">Authorization & Approval</div>
  <p style="font-size:13px;color:#5f6368;margin-bottom:24px;">This document has been reviewed and approved by the undersigned officers of Skolyn.</p>
  <div class="signature-grid">
    <div class="signature-block"><div class="role">Chief Technology Officer (CTO)</div><div class="name">Skolyn Technology Division</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
    <div class="signature-block"><div class="role">Chief Executive Officer (CEO)</div><div class="name">Skolyn Executive Office</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
  </div>
</div>

<div class="doc-footer"><p><strong>Skolyn</strong> â€” Redefining Medical Imaging Through Explainable AI</p><p>Document ID: SKL-AI-002 | Version 3.0 | Classification: Confidential</p><p>&copy; 2026 Skolyn. All rights reserved.</p></div>

</body>
</html>
